Author | William Kevin Kelly, DO | OncLive

Author | William Kevin Kelly, DO

Articles

Dr. Kelly on Radium-223 Dichloride and Niraparib in Patients With mCRPC

June 09, 2020

Video

William K. Kelly, DO, discusses results from a phase 1b dose-finding study (NCT03076203) evaluating the combination of radium-223 dichloride (Xofigo) plus niraparib (Zejula) in patients with metastatic castration-resistant prostate cancer.

Dr. Kelly on the Rationale for Combining Radium-223 and Niraparib in mCRPC

June 05, 2020

Video

William Kevin Kelly, DO, discusses the rationale for a phase 1b dose-finding study evaluating the combination radium-223 dichloride and niraparib in patients with metastatic castration-resistant prostate cancer.

Dr. Kelly on the Importance of Local Control in Locally Advanced Prostate Cancer

April 10, 2018

Video

William Kevin Kelly, DO, professor of medical oncology and urology, Thomas Jefferson University, director, Division of the Solid Tumor Oncology, Sidney Kimmel Cancer Center, discusses the evolution of local control in locally advanced prostate cancer.

Dr. Kelly on Selecting Therapy for Patients with CRPC

November 27, 2013

Video

William Kevin Kelly, DO, professor of medical oncology and urology, Thomas Jefferson University, discusses the possibility of preselecting which castration-resistant prostate cancer (CRPC) patients will be sensitive to chemotherapy or hormone therapy.

x